Disclaimer
The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
ISIN: XXXXXXXXXXXXX-XXXX Updated at 11:05:33
XXXXX.XX
For more information, please consult Euronext
Status as of 14 November 2024
Last update: 21 October 2024
This graph represents Sequana Medical’s major shareholders, based on transparency notifications received by the Company, to date.
The Belgian Transparency Act refers to article 14 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings in issuers shares of which are admitted to trading on a regulated market and laying down miscellaneous provision.
Pursuant to this Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.
For more information and the appropriate transparency forms, please contact Sequana Medical Investor Relations (ir@sequanamedical.com) or the FSMA.
| Shareholder | Date of notification | Transparency notification | Press release |
| Sensinnovat BV | 7-Oct-2024 | Download pdf | 10-Oct-2024 |
| Newton Biocapital | 06-Aug-2024 | Download pdf | 9-Aug-2024 |
| Pi Equity | 30-July-2024 | Download pdf | 1-Aug-2024 |
| GRAC | 29-July-2024 | Download pdf | 5-Aug-2024 |
| FPIM-SFPI | 16-July-2024 | Download pdf | 19-July-2024 |
| Adrianus van Herk | 08-Apr-2024 | Download pdf | 11-Apr-2024 |
| EQT Life Sciences Group B.V. | 10-Apr-2024 | Download pdf | 11-Apr-2024 |
| EQT Life Sciences Group B.V. | 04-Apr-2024 | Download pdf | 11-Apr-2024 |
| LSP Management Group B.V. | 08-Apr-2024 | Download pdf | 11-Apr-2024 |
| Optiverder B.V. | 03-Apr-2024 | Download pdf | 08-Apr-2024 |
| Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA | 02-Apr-2024 | Download pdf | 08-Apr-2024 |
| GRAC société simple | 28-Mar-2024 | Download pdf | 08-Apr-2024 |
| ParticipatieMaatschappij Vlaanderen NV | 03-Apr-2024 | Download pdf | 03-Apr-2024 |
| Adrianus van Herk | 28-Mar-2024 | Download pdf | 03-Apr-2024 |
| MCMI | 19-Jan-2024 | Download pdf | 24-Jan-2024 |
| Erik Amble / NeoMed Management / NeoMed IV | 16-Jan-2024 | Download pdf | 24-Jan-2024 |
| Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA | 11-Jan-2024 | Download pdf | 15-Jan-2024 |
| Optiverder BV | 10-May-2023 | Download pdf | 15-May-2023 |
| Participatiemaatschappij Vlaanderen NV | 11-May-2023 | Download pdf | 15-May-2023 |
| NeoMed IV Extension Limited / NeoMed Innovation V Limited | 06-Feb-2023 | Download pdf | 09-Feb-2023 |
| Rosetta Capital Ltd | 06-Feb-2023 | Download pdf | 09-Feb-2023 |
| GRAC société simple | 22-Mar-2022 | Download pdf | 28-Mar-2022 |
| Partners in Equity V B.V. | 16-Mar-2022 | Download pdf | 18-Mar-2022 |
| Newton Biocapital I SA | 15-Mar-2022 | Download pdf | 18-Mar-2022 |
| Sensinnovat BV | 15-Mar-2022 | Download pdf | 18-Mar-2022 |
| NeoMed IV Extension Limited / NeoMed Innovation V Limited | 14-Mar-2022 | Download pdf | 18-Mar-2022 |
| Venture Incubator AG / VI Partners AG | 19-Feb-2021 | Download pdf | 23-Feb-2021 |
| LSP Health Economics Fund Management B.V. | 19-Feb-2021 | Download pdf | 23-Feb-2021 |
| NeoMed IV Extension L.P. / NeoMed Innovation V L.P. | 19-Feb-2021 | Download pdf | 23-Feb-2021 |
| Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA | 18-Feb-2020 | Download pdf | 21-Feb-2020 |
| Capricorn Heath-tech Fund NV / Quest for Growth NV | 14-Feb-2020 | Download pdf | 21-Feb-2020 |
| GRAC Société Simple | 30-Jan-2020 | Download pdf | 03-Feb-2020 |
| NeoMed IV Extension L.P. / NeoMed Innovation V L.P. | 30-Jan-2020 | Download pdf | 03-Feb-2020 |
| Newton Biocapital I Pricav Privée SA | 21-Feb-2019 | Download pdf | 25-Feb-2019 |
| Venture Incubator AG / VI Partners AG | 21-Feb-2019 | Download pdf | 25-Feb-2019 |
| NeoMed IV Extension L.P. / NeoMed Innovation V L.P. | 20-Feb-2019 | Download pdf | 25-Feb-2019 |
| LSP Health Economics Fund Management B.V. | 19-Feb-2019 | Download pdf | 25-Feb-2019 |
| Federale Participatie- en Investeringsmaatschappij N.V. | 18-Feb-2019 | Download pdf | 25-Feb-2019 |
| Participatiemaatschappij Vlaanderen NV | 18-Feb-2019 | Download pdf | 25-Feb-2019 |
| Capricorn Health-tech Fund NV / Quest for Growth NV | 18-Feb-2019 | Download pdf | 25-Feb-2019 |
May 23, 2024
Outstanding Shares and Voting Rights NL/EN
XBRL Annual report 2023 – European Single Electronic Format (ESEF) – Dutch only
Statutory annual accounts for the year ended 31 December 2023
Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2023
Statutory auditor’s report on the annual accounts for the year ended 31 December 2023
Report of the Board of Directors on the annual accounts for the year ended 31 December 2023
November 10, 2023
Outstanding Shares and Voting Rights NL/EN
Special report of the Board of Directors
Report of the Board of Directors
June 26, 2023
Outstanding Shares and Voting Rights NL/EN
May 25, 2023
Outstanding Shares and Voting Rights NL/EN
Annual report 2022 – European Single Electronic Format (ESEF) – Dutch only
Statutory annual accounts for the year ended 31 December 2022
Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2022
Statutory auditor’s report on the annual accounts for the year ended 31 December 2022
Report of the Board of Directors on the annual accounts for the year ended 31 December 2022
February 10, 2023
Outstanding Shares and Voting Rights NL/EN
Report of the Board of Directors
Report of the Statutory Auditor
May 27, 2022
Outstanding Shares and Voting Rights NL/EN
Annual report 2021 – European Single Electronic Format (ESEF) – Dutch only
Statutory annual accounts for the year ended 31 December 2021
Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2021
Statutory auditor’s report on the annual accounts for the year ended 31 December 2021
Statutory auditor’s report on the Bootstrap Warrants
Report of the Board of Directors on the annual accounts for the year ended 31 December 2021
Report of the Board of Directors on the renewal of the authorised capital
Report of the Board of Directors on the Bootstrap Warrants
May 27, 2021
Outstanding Shares and Voting Rights NL/EN
Statutory annual accounts for the year ended 31 December 2020
Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2020
Statutory auditor’s report on the annual accounts for the year ended 31 December 2020
Statutory auditor’s report on the 2021 Share Options (full version in Dutch only)
Report of the Board of Directors on the annual accounts for the year ended 31 December 2020
Report of the Board of Directors on the renewal of the authorised capital
Report of the Board of Directors on the 2021 Share Options
May 28, 2020
Outstanding Shares and Voting Rights
Statutory annual accounts for the year ended 31 December 2019
Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2019
Statutory auditor’s report on the annual accounts for the year ended 31 December 2019
May 23, 2019
Vote by Mail Form EN / Vote by Mail Form NL (please complete the Dutch form)
Outstanding Shares and Voting Rights
Attendance Form EN / Attendance Form NL (please complete the Dutch form)
Statutory annual accounts for the year ended 31 December 2018
Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2018
Statutory auditor’s report on the annual accounts for the year ended 31 December 2018
April 25, 2019
Proxy Form EN / Proxy Form NL (please complete the Dutch form)
Vote by Mail Form EN / Vote by Mail Form NL (please complete the Dutch form)
Outstanding Shares and Voting Rights
Attendance Form EN / Attendance Form NL (please complete the Dutch form)
November 14, 2024
Belfius Loan Conversion – Auditor Report art.7:179 (Dutch)
Belfius Loan Conversion – Auditor Report art.7:197 (Dutch)
October 21, 2024
Retention Shares – Board Report (Dutch)
Retention shares – Auditor Report (Dutch)
July 5, 2024
Retention Shares – Board Report (Dutch)
Retention shares – Auditor Report (Dutch)
March 25, 2024
Report of the Board of Directors
Report of the Statutory Auditor (Dutch only)
November 6, 2023
Report of the Board of Directors (Dutch only)
Report of the Statutory Auditor (Dutch only)
October 4, 2023
Report of the Board of Directors (Dutch only)
Report of the Statutory Auditor (Dutch only)
April 24, 2023
Report of the Board of Directors
Report of the Statutory Auditor
March 07, 2022
Report of the Board of Directors
Report of the Statutory Auditor
March 25, 2021
Report of the Board of Directors – Dutch only
Report of the Statutory Auditor – Dutch only
February 9, 2021
Report of the Board of Directors
Report of the Statutory Auditor – full version in Dutch only
January 27, 2020
Report of the Board of Directors
Report of the Statutory Auditor on the proposal of a capital increase (within the framework of the authorized capital) with cancellation of the preferential subscription right – full version in Dutch only
